| Placebo | TS-141 30 mg | TS-141 60 mg | TS-141120 mg | |||
---|---|---|---|---|---|---|---|
(N = 52) | (N = 54) | (N = 52) | (N = 53) | ||||
ADHD RS-IV-J:I | Â | Â | Difference with placebo | Â | Difference with placebo | Â | Difference with placebo |
Start of the study (Mean ± SD) | 34.7 ± 6.4 | 33.4 ± 7.4 | – | 34.9 ± 7.1 | – | 32.3 ± 5.8 | – |
Change from Baseline (Point estimate [95%CI] (p-value)) | |||||||
 Week 2 | −3.8 [−5.6 - -2.1] | − 3.6 [− 5.3 - -1.9] | 0.2 [− 1.8–2.2] (p = 0.830) | −3.1 [− 4.9 - -1.3] | 0.7 [−1.3–2.7] (p = 0.488) | −4.2 [− 5.9 - -2.4] | −0.3 [− 2.3–1.7] (p = 0.735) |
 Week 4 | −6.0 [− 8.4 - -3.6] | −4.7 [− 6.9 - -2.5] | 1.3 [−1.3–3.8] (p = 0.321) | −3.9 [− 6.2 - -1.5] | 2.1 [−0.4–4.7] (p = 0.104) | −6.2 [− 8.5 - -3.9] | −0.2 [− 2.8–2.3] (p = 0.849) |
 Week 8 | −9.1 [− 11.9 - -6.2] | −6.9 [− 9.6 - -4.2] | 2.2 [− 0.8–5.2] (p = 0.158) | −5.4 [− 8.1 - -2.6] | 3.7 [0.6–6.7] (p = 0.018) | −9.0 [− 11.7 - -6.3] | 0.0 [− 3.0–3.0] (p = 0.986) |
 End of the study | −8.0 [− 10.6 - -5.4] | − 6.0 [− 8.5 - -3.5] | 2.0 [− 0.9–4.8] (p = 0.183) | −4.9 [− 7.5 - -2.3] | 3.1 [0.2–6.0] (p = 0.037) | −8.5 [− 11.0 - -5.9] | − 0.5 [− 3.4–2.4] (p = 0.748) |